Interventional Oncology Market

The report "Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 2029", is projected to reach USD 4.24 billion in 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% between 2024 and 2029.

Browse 571 market data Tables and 63 Figures spread through 455 Pages and in-depth TOC on "Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/interventional-oncology-market-203687164.html

With the surging consumption of poultry meat and eggs around the world, particularly in the emerging economies where such products are the major source of protein, the demand for poultry pharmaceuticals is on the rise. This growth leads to an increase in the extent of poultry farming which in regard to the degree of risk of infections levels such as Newcastle disease and Coccidiosis that poultry has calls for appropriate disease management interventions. The increased concern on food safety and the reduction of antibiotic usage has prompted farms to seek alternatives such as probiotics, immune boosters and advanced vaccines for sustainable health management of the flocks. Furthermore, health care marketers are taking note of the growth of the poultry industry in most of the countries and are introducing new health care solutions in these countries aimed at improving production as well meeting regulatory requirements in the production process which has further boosted the growth of the market.

Embolization Devices segment is expected to account for the largest share, by devices & consumables in the interventional oncology market during the forecast period.

Embolization devices hold the upper hand in interventional oncology, due to their high impact on treatments being provided within less invasive parameters about cancer; that is why this has proved far more useful for most surgeons comparing them to those surgical processes taken out over such procedures. The popularity of embolization procedures, TACE and radioembolization, or selective internal radiation therapy, is rising due to demonstrated efficacy in cancers that are considered inoperable, and more specifically in cases of liver cancer. Improvements in embolic materials, drug-eluting beads, and radioactive microspheres have made for more precise delivery of the therapy and have allowed for improved clinical outcomes, increasing their usage as well.

Liver cancer segment is expected to account for the largest share, by cancer type in the interventional oncology market during the forecast period.

Liver cancer is the largest segment of the interventional oncology market due to its increasing incidence worldwide, high mortality rate, and growing need for effective, minimally invasive interventions. The most common type of liver cancer, hepatocellular carcinoma, has a strong association with chronic hepatitis B and C infections, excessive alcohol consumption, and the increasing prevalence of non-alcoholic fatty liver disease. The specialty treatments from interventional oncology include TACE, TARE, and percutaneous ablation-all proven successful treatment for unresectable liver cancer. These give the advantages of localized control, fewer systemic side effects, and a better rate of survival when compared to standard chemotherapy.

Transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT)  segment is expected to account for the largest share, by procedure in the interventional oncology market during the forecast period.

TARE, or selective internal radiation therapy, is the leader in the interventional oncology market, given its established efficacy in the treatment of primary and secondary liver cancers, which account for a significant portion of cancer-related deaths worldwide. The procedure consists of the injection of microspheres loaded with radioactive isotopes, usually Yttrium-90, into the hepatic artery supplying the tumor. This targeted approach delivers localized radiation, maximizes tumor destruction, minimizes systemic exposure, and protects healthy tissues. The preference for TARE is increasing because of its better safety profile, better tolerance, and fewer side effects compared with conventional chemotherapy and external beam radiation. TARE is also particularly useful in patients with unresectable HCC and metastatic colorectal cancer to the liver, whom other therapies are less effective or unavailable.

Hospitals segment is expected to account for the largest share, by end user in the interventional oncology market during the forecast period.

Hospitals have the highest market share of interventional oncology, primarily because they possess strong infrastructural setup, superior technology, and multi-disciplinary skills required to carry out the most complex interventions. Specialized treatments such as TACE, TARE, and tumor ablation depend on state-of-the-art imaging technology, catheterization facilities, and the highly skilled expertise of interventional radiologists. Dedicated cancer hospitals and tertiary care centers possess these capabilities particularly well, thereby becoming the number one interventional oncology providers. Additionally, hospitals provide the full continuum of care from diagnosis to treatment to post-procedure management and follow-up for decades, making it the destination for an enormously diverse patient population seeking integrated solutions for cancer.

In 2023, North America accounted for the largest share of the interventional oncologymarket.

North America dominates the interventional oncology market. It has well-advanced healthcare system, high usage of advanced medical technology, and increasing cancer incidence. The largest market in North America is the United States, with a robust, specialized network of cancer centers and hospitals being abreast with current interventional radiology setup. The increasing incidence of liver, lung, and kidney cancers—the most targeted areas in interventional oncology—have generated increased demand for the use of minimal access techniques like TACE, TARE, and thermal ablation. Further, the fact that such advanced professionals as interventional radiologists and oncologists are present within the country's health sector accelerates market growth.

Key Market Players:

The key players in the global interventional oncology market are Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US), Cook (US), Icecure Medical (Israel), Olympus Corporation (Japan), Imbiotechnologies Ltd (Canada), Medwaves Inc (US), Minimax Medical Limited (China), ABK Biomedical Inc (Canada), RF Medical Co., Ltd (South Korea), Profound Medical (Canada), Surgnova (China), STARmed America (US), Sirtex SIR-Spheres Pty Ltd (US), Accuray Incorporated (US), Guerbet (France), Embolx, Inc (Canada) and Sonablate Corp (US)

Don’t miss out on business opportunities in Interventional Oncology Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com